Vumerity Capsule
NDC Package 64406-020-01
Package Information
Vumerity (diroximel fumarate) capsules is diroximel fumarate is used to treat multiple sclerosis (MS). This formulation utilizes a capsule delivery system. Marketed by Biogen Inc., this product is identified by NDC 64406-020 and is authorized under FDA application NDA211855.
Identification & Billing
- RxCUI: 2261788 - diroximel fumarate 231 MG Delayed Release Oral Capsule
- RxCUI: 2261794 - VUMERITY 231 MG Delayed Release Oral Capsule
- RxCUI: 2261794 - diroximel fumarate 231 MG Delayed Release Oral Capsule [Vumerity]
- RxCUI: 2261794 - Vumerity 231 MG Delayed Release Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 64406 - Biogen Inc.
- 64406-020 - Vumerity
- 64406-020-01 - 1 BOTTLE, PLASTIC in 1 CARTON / 106 CAPSULE in 1 BOTTLE, PLASTIC
- 64406-020 - Vumerity
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (64406-020). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64406-020-01 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 106 capsule in 1 bottle, plastic of Vumerity, a human prescription drug labeled by Biogen Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This capsule is formulated for oral use and contains diroximel fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Biogen Inc. on October 29, 2019. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Diroximel fumarate is used to treat multiple sclerosis (MS). It is not a cure for MS. It helps decrease the number of episodes of worsening MS.
How is this Biogen Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64406002001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.